Measuring the funding and uptake of cancer research activity
Research studies and clinical trials are essential for evaluating the safety and efficacy of emerging cancer therapies and protocols, paving the way for best practices. Participation by the patient population in clinical trials can enable the evolution of best practice treatments and present patients with enhanced treatment options, which in turn can improve outcomes for future patients.
Here you will find indicators that can be considered proxy system performance indicators of cancer research activity. In addition, because adequate funding for research to various types of cancer is essential to a successful research environment, another indicator measures the allocation of site-specific research investments relative to disease burden.